UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 333-147193

 

 

FluoroPharma Medical Inc.

 

(Exact name of registrant as specified in its charter)

 

701 S CARSON ST, STE 200, Carson City, NV, 89701

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) [X]
Rule 12g-4(a)(2) [   ]
Rule 12h-3(b)(1)(i) [   ]
Rule 12h-3(b)(1)(ii) [   ]
Rule 15d-6 [   ]
Rule 15d-22(b) [   ]

 

Approximate number of holders of record as of the certification or notice date: 49  

 

Pursuant to the requirements of the Securities Exchange Act of 1934 FluoroPharma Medical Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

Date:  October 12, 2022   By: /s/ Ambrose O. Egbuonu
    Executive Chairman

 

 

FluoroPharma Medical (CE) (USOTC:FPMI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse FluoroPharma Medical (CE)
FluoroPharma Medical (CE) (USOTC:FPMI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse FluoroPharma Medical (CE)